People · Operator
Named in public records as an officer, director or promoter · active 2015–2023 · Biotechnology, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Balance Therapeutics, Inc. | — | Biotechnology | Series B | $21.2M | $7.3M | 2015 |
| Nalu Bio, Inc. | — | Biotech / Pharma | Series A | $4.8M | $48.4M | 2023 |
Phyllis E. Whiteley at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Phyllis E. Whiteley on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Grey | 1 | 10 |
| Richard Chin | 1 | 4 |
| Caitlyn Krebs | 1 | 1 |
| Peter E. Carlton | 1 | 1 |
| Lyndon Lien | 1 | 1 |
| Randall S. Ussery | 1 | 1 |
| Howard E. Goodwin | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.